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Our objective was to evaluate the role of soluble guanylate cyclase (sGC) activation in the gastro-
protective effect of the HO-1/CO pathway against alendronate-induced gastric damage in rats. Rats
were pretreated, once daily for 4 days, with saline, hemin (HO-1 inducer), or dimanganese decacarbonyl
(DMDC, CO donor). Another group received zinc protoporphyrin IX (ZnPP IX, HO-1 antagonist) 1 h
before hemin treatment or sGC inhibitor (ODQ) 30 min before hemin and DMDC treatment. After
30 min, gastric damage was induced by alendronate (30 mg/kg) by gavage. On the last day of treatment,
4 h after alendronate administration, the animals were killed. Gastric lesions were measured using a
computer planimetry program, and gastric corpus pieces were assayed for malondialdehyde (MDA),
glutathione (GSH), pro-inﬂammatory cytokines (tumor necrosis factor [TNF]-a and interleukin [IL]-1b),
myeloperoxidase (MPO), or bilirubin. Another group was used to measure gastric mucus. HO-1
expression was determined after saline or alendronate administration by immunohistochemistry.
Alendronate induced gastric damage, produced neutrophil accumulation, increased MDA levels and
MPO activity, and reduced GSH and mucus in the gastric tissue. Alendronate also increased HO-1
immunoreactivity and the level of bilirubin in gastric mucosa. Pretreatment with hemin or DMDC
reduced neutrophil inﬁltration and TNF-a, IL-1b, and MDA formation, and increased the levels of GSH
and mucus in the gastric tissue. ODQ completely abolished the gastroprotective effect of hemin and
DMDC and increased alendronate gastric damage. Our results suggest that the HO-1/CO pathway plays
a protective role against alendronate-induced gastric damage through mechanisms that can be
dependent on sGC activation.
& 2012 Elsevier B.V. Open access under the Elsevier OA license. 1. Introduction
Bisphosphonates are a class of compounds widely used in the
treatment of diseases related to bone remodeling, e.g., osteoporosis
and Paget’s disease (Aihara et al., 2007; Russell, 2006). However,
these compounds cause serious adverse effects in patients, including
inﬂammation, gastric ulcer, nausea, and abdominal pain in the upper
gastrointestinal tract, although the mechanism underlying these
reactions remains unknown (Graham, 2002; Marshall et al., 2000).55 86 33234750;
deiros).
ier OA license. It has been demonstrated that the potential to damage the
gastric mucosa is different between bisphosphonates; among
these drugs, alendronate seems to have more potential for
causing such effect (Lanza et al., 2000; Graham and Malaty,
1999; Graham, 2002). The use of alendronate is associated with
irritant effects on the esophagus, stomach, and duodenum (Jeal
et al., 1997; Lanza et al., 2000; Graham, 1998). In some cases,
severe ulceration has been reported (De Groen et al., 1996).
Adverse effects of alendronate in the upper gastrointestinal tract
have been attributed in many cases to adherence of the drug to
the mucosal surface (Jeal et al., 1997).
Heme oxygenase-1 (HO-1) is a stress-inducible protein, which
catalyzes oxidative degradation of heme, thereby eliminating
the potentially toxic free-heme, but releasing biliverdin, carbon
monoxide (CO), and ferrous iron. Biliverdin is then converted to
bilirubin by biliverdin reductase (Pae and Chung, 2009). Biliverdin
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HO-1 has been identiﬁed in the gastric mucosa and participates in
a number of cellular defense mechanisms (Guo et al., 2003; Morse
and Choi, 2002; Becker et al., 2003). Induction of HO-1 in several
animal models of diseases has been shown to protect tissues and
cells against oxidative stress, inﬂammation, ischemia/reperfusion
injury, transplant rejection, and apoptosis (Otterbein and Choi,
2000; Wagener et al., 2003).
CO is known to be an activator of soluble guanylate cyclase (sGC),
which results in increased cyclic guanosine 3050-cyclic monopho-
sphate (cGMP) production. The physiological function of the
CO/sGC/cGMP pathway has become the subject of intensive research
in recent years, and studies on the gastrointestinal tract have been
an important focus of investigations (Gibbons and Farrugia, 2004). In
addition, it has been suggested that CO may also have anti-
inﬂammatory properties, including decreased free radical produc-
tion and inhibition of proinﬂammatory cytokine expression (Gomes
et al., 2010; Kirkby and Adin, 2006; Ryter et al., 2007).
Recently, studies show that CO contributes to maintaining
gastric mucosal against ethanol-induced gastric damage and
NSAIDs and this beneﬁcial effect of CO seems to depend on cGMP
activation (Gomes et al., 2010; Uc et al., 2012; Aburaya et al., 2006).
However, the participation of this gaseous mediator in
alendronate-induced gastric damage is unknown.
Considering that there is still no fully effective therapy for
gastropathy caused by alendronate and there are few studies on
the mechanisms involved in its toxicity, the aim of this study was
to evaluate the role of sGC activation in the gastroprotective
activity of the HO-1/CO pathway against alendronate-induced
gastric damage in rats.2. Material and methods
2.1. Animals
Male Wistar rats, weighing 180–200 g, were obtained from the
Department of Physiology and Pharmacology, Federal University
of Ceara´. The animals were housed in cages in a temperature-
controlled environment under a 12 h light/12 h dark cycle.
The animals had free access to drinking water and standard pellet
diet (Purina chow). The animals were deprived of food for
18–24 h before the experiment, but had free access to water.
All animal treatments and surgical procedures were performed in
accordance with the Guide for Care and Use of Laboratory Animals
(National Institutes of Health, Bethesda, MD) and were approved
by the local ethics committee (Protocol No. 0067/10).
2.2. Drugs and solutions
ZnPP IX, Ferriprotoporphyrin IX chloride (hemin), dimanganese
decacarbonyl (DMDC), 1 H-[1,2,4]oxadiazolo[4,3-a]quinoxaline-1-
one (ODQ), glibenclamide, and alendronate were purchased from
Sigma (St. Louis, MO). Hemin was dissolved in 1 mM NaOH, DMDC
and ODQ in 0.01% DMSO. Glibenclamide was dissolved in 0.01 N
NaOH containing 4% glucose. Alendronate was dissolved in saline
and adjusted to pH 7.0 by adding NaOH or HCl (Kanatsu et al., 2004).
2.3. Effect of CO on alendronate-induced gastric damage
The animals were initially treated with hemin (HO-1 inducer:
1, 3, and 10 mg/kg, i.p.), DMDC (CO donor: 9, 27, and 81 mmol/kg,
i.p.), or an equivalent volume of their respective vehicles. After
30 min, the rats received alendronate (30 mg/kg, pH 7.0) by
gavage. All drugs were administered once daily for 4 days
(adapted from Sener et al., 2004). On the last day of treatment,4 h after alendronate administration, the animals were killed and
their stomachs removed. Gastric damage was measured using a
computer planimetry program (Image J). A sample of the stomach
was ﬁxed in 10% formalin immediately after its removal for
subsequent histopathological assessment and immunohistochem-
istry for HO-1. Other samples were then weighed, frozen, and
stored at 70 1C until assayed for glutathione (GSH) (Sedlak and
Lindsay, 1968), malondialdehyde (MDA) (Mihara and Uchiyama,
1978), myeloperoxidase activity (Bradley et al., 1982), and cytokine
concentrations (Cunha et al., 1993).
2.4. Role cGMP in the gastroprotective effect of CO
To investigate the role of cGMP in the gastroprotective effect of
CO, rats were pretreated with ODQ (guanylate cyclase inhibitor:
10 mg/kg, i.p.). One hour before, the rats received hemin (HO-1
inducer: 10 mg/kg, i.p.) or DMDC (CO donor: 81 mmol/kg, i.p.).
After 30 min, the animals received alendronate (30 mg/kg, pH 7.0)
by gavage. The control group received only saline or dimethyl
sulfoxide (DMSO, 0.01%) plus alendronato or ODQ plus alendro-
nate. All drugs were administered once daily for 4 days. On the
4th day of treatment, 4 h after alendronate administration, the
animals were killed, their stomachs removed, and gastric damage
was determined as described above. In other groups, the sto-
machs were removed for measurement of the amount of mucus
adhered to the gastric wall (Corne et al., 1974).
2.5. Role of HO-1 on the gastroprotective effect of hemin
To study the role of HO-1 on the gastroprotective effect of hemin,
rats were pretreated with HO-1 antagonist (ZnPP IX: 1 mg/kg, i.p.).
One hour after, rats were treated with hemin (10 mg/kg, p.o.). After
30 min, the animals received alendronate (30 mg/kg, pH 7.0) by
gavage. The control group received only saline or ZnPP IX plus
alendronate. All drugs were administered once daily for 4 days. On
the 4th day of treatment, 4 h after alendronate administration, the
animals were killed, their stomachs removed, and gastric damage
was determined as described above.
2.6. Histological evaluation of gastric lesions
For histological evaluation, stomach samples were ﬁxed in 10%
formalin solution, where they remained for 24 h. After this
procedure, the samples were transferred to a solution of alcohol
70%. Then, the samples were embedded in parafﬁn and sectioned.
Four-micrometer-thick sections were deparafﬁnized, stained with
hematoxylin and eosin, and then examined under a microscope.
The specimens were assessed according to the criteria of Laine
and Weinstein (1988), who assigned scores according to the
following parameters: epithelial cell loss (a score of 0–3), edema
in the upper mucosa (a score of 0–4), hemorrhagic damage
(a score of 0–4), and presence of inﬂammatory cells (a score of
0–3), yielding a maximum total score of 14. Afterward, the
sections were assessed by an experienced pathologist who was
blinded to the treatment.
2.7. Immunohistochemistry for HO-1
The samples from the stomach of rats undergoing alendronate-
induced gastric damage were assessed for the expression of HO-1
by employing an immunohistochemical technique. The slides
mounted from the parafﬁn blocks were deparafﬁnized and then
hydrated. Endogenous peroxidase activity was blocked with 1%
H2O2 diluted in methanol. Then, the slides were washed in
phosphate-buffered saline (PBS). Next, the slides were incubated
with primary antibody (1:400, Santa Cruz Biotechnology, Santa
N.R.D. Costa et al. / European Journal of Pharmacology 700 (2013) 51–59 53Cruz, CA) overnight at 4 1C. After washing, the slides were
incubated with biotinylated secondary antibody, diluted in PBS
plus bovine serum albumin (PBS-BSA). Negative control sections
were processed simultaneously as described above, but without
adding an antibody. Finally, the tissue was stained for antigen-
antibody complexes using a peroxidase detection system and
then viewed under a microscope.
2.8. Glutathione analysis
The reduced glutathione (GSH) content of stomach tissues was
estimated according to the method described by Sedlak and
Lindsay (1968). Brieﬂy, 50–100 mg of frozen gastric tissue was
homogenized in 1 ml of 0.02 M EDTA for each 100 mg of tissue.
Aliquots (400 ml) of the homogenate were mixed with 320 ml of
distilled water and 80 ml of 50% (w/v) trichloroacetic acid to
precipitate proteins. The tubes were centrifuged at 3000 rpm for
15 min at 4 1C. Supernatants (400 ml) were mixed with 800 ml of
Tris buffer (0.4 M, pH 8.9) and 20 ml of 5,50-dithiobis(2-nitroben-
zoic acid) (DTNB, 0.01 M). The mixture was then stirred for 3 min
and the absorbance was read at 412 nm using a spectrophot-
ometer. The results were expressed as micrograms of GSH per
gram of tissue.
2.9. Malondialdehyde analysis
The level of malondialdehyde (MDA) in the homogenates from
each group was measured using the method of Mihara and
Uchiyama (1978), which is based on the reaction with thiobarbi-
turic acid. Fragments of gastric mucosa weighing between 100
and 150 mg were homogenized with cold KCl (1.15%) to prepare a
10% solution of homogenate. In brief, 250 ml of this homogenate
was added to 1.5 ml of 1% H3PO4 and 0.5 ml of 0.6% thiobarbituric
acid (aqueous solution). Then, the mixture was stirred and heated
in a boiling water bath for 45 min. Next, the reaction mixture was
cooled immediately in an ice water bath, followed by addition of
4 ml of n-butanol. This mixture was shaken for 1 min, and the
butanol layer was separated by centrifugation at 1200g for
10 min. Optical density was determined at 535 and 520 nm, and
the optical density difference between the 2 determinations was
calculated and considered as thiobarbituric acid value. MDA
concentrations were expressed as nanomoles per gram of tissue.
2.10. Myeloperoxidase activity
Myeloperoxidase (MPO) is an enzyme found primarily in
neutrophil azurophilic granules. It has been used extensively as
a biochemical marker for granulocyte inﬁltration into various
tissues, including the gastrointestinal tract. The extent of neutro-
phil accumulation in the gastric mucosa was measured by MPO
activity evaluation as previously described (Bradley et al., 1982).
Brieﬂy, 50–100 mg of tissue was homogenized in 1 ml of potas-
sium phosphate buffer (50 mM, pH 6.0) with 0.5% of hexadecyl-
trimethylammonium bromide (HTAB) for each 50 mg of tissue.
Then, homogenates were centrifuged at 40,000g for 7 min at 4 1C.
MPO activity in the resuspended pellet was assayed by measuring
the change in absorbance at 450 nm using o-dianisidine dihy-
drochloride and 1% hydrogen peroxide. The results were reported
as MPO units/mg of tissue. A unit of MPO activity was deﬁned as
that converting 1 mmol of H2O2 to water in 1 min at 22 1C.
2.11. Bilirubin determination in tissue
Brieﬂy, 100 mg of frozen gastric tissue were homogenized in
1 ml of saline. Aliquots (500 ml) of homogenates were added to
250 mg of BaCl2 and vortex-mixed thoroughly, as described byForesti et al. (2003) with some modiﬁcations. Then, 0.75 ml of
benzene was added to the mixtures, and the tubes were vigorously
vortex-mixed again. The benzene phase containing extracted bilir-
ubin was separated from the aqueous phase by centrifugation at
13,000g for 30 min. A standard bilirubin curve was obtained using
commercial bilirubin (Labtest, Brazil). Bilirubin was measured
spectrophotometrically, as absorbance difference between 450
and 600 nm and expressed as mg/dl (Foresti et al., 2003).
2.12. Measurement of the amount of mucus adhered to the gastric
wall
The mucus adhered to the gastric wall in the alendronate-
induced damage model was determined according to the method
of Corne et al. (1974). Glandular segments from stomachs were
collected and weighed. Each segment was transferred to 1% Alcian
blue solution (0.16 M sucrose in 0.05 M sodium acetate, pH 5.8).
Excess dye was removed by washing the segments with 0.25 M
sucrose solution. The mucus dye complex was extracted by
placing the segments in 0.5 M MgCl2 for 2 h. The dye extract
was mixed with diethyl ether, centrifuged at 1400g for 10 min,
and absorbance of the supernatants was measured at 598 nm.
The quantity of extracted Alcian blue (mg/g of glandular tissue)
was then calculated using a standard curve of Alcian blue.
2.13. Cytokine measurements
The animals had a sample of their stomach removed on day
4 for analysis of cytokines. The specimens were stored at 70 1C
until required for assay. The collected tissues were homogenized
and processed as described by SaWeh-Garabedian et al. (1995).
The concentration of tumor necrosis factor (TNF)-a and inter-
leukin (IL)-1b was determined by using an enzyme-linked immu-
nosorbent assay (ELISA), as described previously (Cunha et al.,
1993). Brieﬂy, microtiter plates were coated overnight at 4 1C
with an antibody against rat TNF-a or IL-1b (4 mg ml1, DuoSet
ELISA Development kit R&D Systems; Catalog DY501 or DY510,
respectively). After blocking the plates, the samples and standards
were added at various dilutions in duplicate and incubated at 4 1C
for 24 h. The plates were washed 3 times with buffer. After
washing the plates, biotinylated sheep polyclonal anti-TNF-a or
anti-IL-1b (diluted 1:1,000 with assay buffer containing 1% bovine
serum albumin [BSA]) was added to the wells. After further
incubation at room temperature for 1 h, the plates were washed
and 50 ml of avidin-conjugated horseradish peroxidase diluted
1:5,000 was added to the wells. The color reagent o-phenylene-
diamine (OPD; 50 ml) was added 15 min later and the plates were
incubated in the dark at 37 1C for 15–20 min. The enzyme
reaction was stopped with H2SO4 and absorbance was measured
at 490 nm. Values are expressed as pictograms of cytokines per
milliliter (pg/ml).
2.14. Statistical analysis
All values are expressed as mean7S.E.M. ANOVA and
Student–Newman–Keuls test were used to determine statistical
signiﬁcance of differences between groups. For histological
assessment, the Kruskal–Wallis nonparametric test was used,
followed by Dunn’s test for multiple comparisons. Differences
were considered to be signiﬁcant when Po0.05.
3. Results
The present study conﬁrmed that alendronate damaged both
the corpus and the antral mucosa of the stomach and this damage
Fig. 1. Hemin (A) and dimanganese decacarbonyl (DMDC) (B) prevents alendro-
nate-induced gastric damage in a dose-dependent manner. Rats were treated by
gavage with hemin or DMDC 30 min before alendronate (30 mg/kg) administra-
tion. Another group received zinc protoporphyrin IX (ZnPP IX, HO-1 antagonist)
1 h before hemin treatment (panel A). The control group was treated with saline
only. All drugs were administered once daily for 4 days. The total area of
macroscopic gastric lesions was determined after 4 days. Results are expressed
as mean7S.E.M. of at least 5 rats per group. (*) Po0.05, when compared to
control. (#) Po0.05, when compared to the alendronate group; (C) Po0.05, when
compared to the hemin plus alendronate group; ANOVA and Newman–Keuls test
were used for evaluation.
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rat gastric mucosa to alendronate for 4 days produced widespread
damage to the epithelium, and the luminal surface was covered
with cellular debris (data not shown). Chronic oral administration
of alendronate caused hemorrhagic lesions in the mucosa of the
glandular stomach, indicating true ulcer formation and this was
also supported by the histopathological ﬁndings (Table 1).
In or study, we demonstrated that hemin (HO-1 inducer) and
DMDC (CO-donor) treatment prevented alendronate-induced
macroscopic and microscopic gastric damage (Fig. 1A and B, and
Table 1). From the microscopic analysis, alendronate increased
hemorrhagic damage, edema, epithelial cell loss, and inﬁltration
of inﬂammatory cells, when compared to the control group.
Hemin and DMDC signiﬁcantly decreased inﬁltration of inﬂam-
matory cells, formation of edema, and epithelial cells loss induced
by alendronate, but other parameters did not change (Table 1).
HO-1 inhibition by ZnPP IX signiﬁcantly reversed the hemin-
mediated protection in both macroscopic and microscopic assess-
ments (Fig. 1A and Table 1). Rats treated with ZnPP IX plus
alendronate showed an increase of gastric damage as in those
treated with alendronate alone (Fig. 1A); however, ZnPP IX alone
had no effect on the gastric damage parameters. Because hemin at
a dose of 10 mg/kg and DMDC at a dose of 81 mmol/kg afforded
the most protection against gastric lesions induced by alendro-
nate, these doses were selected for the study of possible mechan-
isms of action involved in CO-mediated gastroprotective effects.
In this study, HO-1-immunoreactive cells were observed in the
gastric mucosa after hemin administration (Fig. 2B, black arrows),
alendronate administration (Fig. 2C, black arrows), or hemin plus
alendronate administration (Fig. 2D, black arrows) when com-
pared with the control group (Fig. 2A) and alendronate treatment
resulted in bilirubin accumulation in gastric tissues (Fig. 2E). Rats
treated with hemin plus alendronate showed an increase in
HO-1-immunoreactive cells as in those treated with alendronate
alone (Fig. 2E). This result demonstrated that hemin alone or
alendronate alone increased HO-1 expression in gastric mucosa
when compared to the control group and hemin plus alendronate
causes a greater induction than alendronate alone (Fig. 2).
In the present study, we investigated whether cGMP partici-
pated in the gastroprotective effects of hemin and DMDC against
alendronate-induced gastric damage. Pretreatment with ODQ, a
sGC inhibitor, signiﬁcantly reversed hemin and DMDC-induced
gastroprotection in alendronate-induced macroscopic and micro-
scopic gastropathy (Fig. 3), but ODQ by itself had no effect on theTable 1
Effect of ODQ (10 mg/kg) and ZnPP (1 mg/kg) pretreatment on protective effect of hemin (10 mg/kg) or DMDC (81 mmol/kg) in alendronate-induced microscopic gastric
damage.
Experimental group Hemorrhagic damage (score 0–4) Edema (score 0–4) Epithelial cell loss (score 0–3) Inﬂammatory cells (score 0–3) Total (score 0–14)
Saline 0 (0–1) 0 0 (0–1) 0 1 (0–2)
Alendronate 3 (1–3)a 3 (2–3)a 3 (2–3)a 2 (2–3)a 9 (7–12)a
Heminþalendronate 2 (1–2) 1 (0–1) 0 (0–2)b 0 (0–1)b 2 (2–5)b
ZnPPþheminþalendronate 3 (1–3) 3 (1–3) 3 (2–3)c 3 (2–3)c 10 (6–12)e
ZnPPþalendronate 3 (2–3) 3 (1–3) 3 (2–3) 3 (2–3) 8 (7–12)
ODQþheminþalendronate 3 (1–3) 2 (2–3)c 3 (2–3)c 2 (2–3)c 10 (7–12)c
DMDCþalendronate 2 (0–2) 0 (0–1)b 0 (0–1)b 0 (0–1)b 2 (2–4)b
ODQþDMDCþalendronate 3 (1–4) 3 (2–3)d 3 (2–3)d 3 (2–3)d 11 (7–13)d
ODQþalendronate 4 (1–4) 3 (2–3) 3 (2–3) 3 (2–3) 10 (7–13)
Data shown are medians with minimal and maximal scores shown in parentheses. Kruskal–Wallis nonparametric test, followed by Dunn’s test was used for multiple
comparisons for histological assessment.
a Po0.05, when compared with control group.
b Po0.05, when compared with alendronate group.
c Po0.05, when compared with Heminplus alendronate group.
d Po0.05, when compared with DMDC plus alendronate group.
Fig. 2. Photomicrographs of gastric mucosa (magniﬁcations, 100) showing HO-1 immunoreactivity was absent in normal gastric tissue (panel A), but HO-1
immunoreactivity was detected in the gastric mucosa tissue after alendronate administration once daily for 4 days (panel B) and hemin (10 mg/kg) administration
once daily for 4 days (panel C). Other group was treated with hemin (10 mg/kg) plus alendronate (panel D) and the HO-1 immunoreactivity was greater than with
alendronate alone. Panel E: Bilirubin levels in rats treatment with saline, hemin, alendronate or heminþalendronate administered once daily for 4 days. (*) Po0.05, when
compared to control (saline). (#) Po0.05, when compared to the alendronate group. ANOVA and Newman–Keuls test were used for evaluation.
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treatment signiﬁcantly increased macroscopic gastric damage when
compared to alendronate alone (Fig. 3). These results suggest that
endogenous HO-1/cGMP pathway is involved on alendronate
induced gastric damage.
Administration of alendronate resulted in reduced GSH levels,
increased MDA concentration and MPO activity (Table 2), and
increased levels of pro-inﬂammatory cytokines (TNF-a and IL-1b,
Fig. 4A and B, respectively) when compared with the control
group. Hemin and DMDC pretreatments reversed the effect of
alendronate on these biochemical parameters. Hemin and DMDC
also reduced the levels of TNF-a and IL-1b (Fig. 4A and B,
respectively). The only treatment with ODQ did not alter the
alendronate-induced changes in cytokines levels and MPOactivity (Table 2 and Fig. 4), but ampliﬁed the effect of alendro-
nate on GSH and MDA levels (Table 2).
Alendronate decreased signiﬁcantly the amount of gastric
adherent mucus when compared to the control group (saline).
DMDC treatment prevented this effect of alendronate. However,
ODQ pretreatment reversed the gastroprotective effect of DMDC.
Mucus amount in these animals was decreased to levels similar to
those in animals of the alendronate group (Fig. 5).4. Discussion
The HO enzyme represent an important anti-inﬂammatory
pathway and has been shown to exhibit powerful protective
Fig. 3. Effect of pretreatment with ODQ on the protective effect of hemin and DMDC against alendronate-induced gastric damage. ODQ (10 mg/kg, i.p.) was injected 1 h
before hemin (10 mg/kg) or DMDC (81 mmol/kg). Thirty minutes later, alendronate (30 mg/kg) was administered. The control group was treated with saline. All drugs were
administered once daily for 4 days. Macroscopic gastric lesions were determined after 4 days. Results are expressed as the mean7S.E.M. of at least 5 animals per group. (*)
Po0.05, when compared to the alendronate group; (#) Po0.05, when compared to the hemin plus alendronate group; (C) Po0.05, when compared to the DMDC plus
alendronate group; ANOVA and Newman–Keuls test.
Table 2
Effect of pretreatment with hemin (10 mg/kg) or dimanganese decacarbonyl
(DMDC) (81 mmol/kg) against alendronate-induced gastric damage in GSH, MDA,







Saline 482.5720.1 71.572.6 7.270.6
Alendronate 180.3721.9a 121.174.3a 31.573.8a
Heminþalendronate 570.3721.6b 99.076.3b 12.072.2b
DMDCþalendronate 482.1773.8b 58.5710.5b 9.470.7b
ODQþheminþalendronate 200.8742.5c 115.272.3c 28.173.3c
ODQþDMDCþalendronate 172.7735.2d 102.578.8d 22.271.9d
ODQþalendronate 109.2713.2b 196.1712.4b 34.276.1
Results are mean7S.E.M. of 5–7 rats.
a Po0.05, when compared with control group.
b Po0.05, when compared with alendronate group.
c Po0.05, when compared with hemin plus alendronate group.
d Po0.05, when compared with DMDC plus alendronate group.
Fig. 4. Treatment with hemin (10 mg/kg) or DMDC (81 mmol/kg) decreased
concentration of TNF-a and IL-1b (A and B, respectively) in alendronate-induced
gastric damage. Rats were treated by gavage with hemin or DMDC 30 min before
alendronate (30 mg/kg) administration. The control group was treated with saline
only. All drugs were administered once daily for 4 days. Results are expressed as
the mean7S.E.M. of at least 5 rats per group. (*) Po0.05, when compared to
control. (#) Po0.05, when compared to the alendronate group. ANOVA and
Newman–Keuls test were used for evaluation.
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(Attuwaybi et al., 2003; Giris et al., 2006; Otterbein et al., 2003).
Various stressors such as oxidative stressors, ultraviolet irradia-
tion, inﬂammatory cytokines, and heavy metals have been
reported to induce HO-1 production (Maines, 1997).
HO-1 degrades heme to CO, free iron, and biliverdin. Both
biliverdin and CO have potent antioxidative, anti-inﬂammatory,
and gastroprotective activity (Ponka, 1999; Maines, 1997; Gomes
et al., 2010). CO mediates the activation of sGC, thereby stimulat-
ing the production of cGMP. The CO/sGC/cGMP pathway has been
implicated in mediating the protective effects of CO (Ryter and
Otterbein, 2004). However, the protective effects of biliverdin do
not depend on activation of sGC (Gomes et al., 2010). Considering
the importance of these enzymes, particularly HO-1, as therapeu-
tic strategy for the protection against inﬂammatory processes and
oxidative tissue damage, we investigated the role of sGC activa-
tion in the gastroprotective effect of the HO-1/CO pathway
against alendronate-induced gastric damage in rats in the present
study.
The mechanism by which bisphosphonates promote lesion for-
mation in the gastric mucosa is still unknown. Our results indicate
that the HO-1/CO/cGMP pathway plays a protective role against
alendronate-induced gastric damage and that these preventive
effects probably result from decreased free radical production and
inﬂammation process in the gastric mucosa. As demonstrated in theliterature related to ethanol-induced gastropathy (Gomes et al.,
2010) and colitis models (Hegazi et al., 2005), HO-1 induction by
hemin, HO-1 product, or CO donor reduced inﬂammatory gastro-
pathy and colonic damage. Likewise, it was veriﬁed that a HO-1
Fig. 5. Effect of pretreatment with ODQ on the protective effect of DMDC on the
levels of mucus in the alendronate-induced gastric damage. ODQ (10 mg/kg) was
administered by gavage 1 h before DMDC (81 mmol/kg). After another 30 min,
alendronate (30 mg/kg) was administered. The control group was treated with
saline only. All drugs were administered once daily for 4 days. Results are
expressed as the mean7S.E.M. of at least 5 animals per group. (*) Po0.05, when
compared to control; (#) Po0.05, when compared to the DMDC plus alendronate
group; ANOVA and Newman–Keuls test.
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ethanol (Gomes et al., 2010) and exacerbated the gastric mucosa
lesions induced by HCl (Ueda et al., 2008)
We conﬁrmed the potential of alendronate to promote lesion
formation in the gastric epithelium. Our results demonstrated that
administration of alendronate (30 mg/kg, once daily for 4 days)
promotes macroscopic and microscopic gastric mucosal damage, i.e.,
formation of hemorrhages and edema, migration of inﬂammatory
neutrophils, and epithelial cell loss. We observed that both CO-
donor (DMDC) and CO precursor (hemin) decreased alendronate-
induced gastropathy. Therefore, we could infer that CO synthesis is
essential for gastric protection against alendronate.
We also demonstrated that alendronate increased HO-1 immu-
noreactivity in gastric mucosal cells, which was conﬁrmed by
bilirubin accumulation, a secondary product of HO-1, in gastric
tissues. Our results are in accordance with the literature. Gomes
et al. (2010) demonstrated that another aggressor agent (ethanol)
increased the levels of HO-1 mRNA transcripts in the gastric
mucosa; they also showed HO-1 immunoreactivity in the lamina
propria, submucosa, and muscle layer. Naito et al. (2011) reported
that local levels of biliverdin and bilirubin are increased after HO-1
induction and this may be beneﬁcial in protecting several types of
cells from injury. Dalton et al. (1999) have reported that in order to
compensate stressors agents, higher animals have evolved physio-
logical defense mechanisms, including expression of antioxidant
proteins and phase II detoxifying enzymes. Induction of phase II
enzymes such as HO-1 renders cells more resistant to potential
subsequent challenges of greater stress (Yeligar et al., 2010).
In fact, alendronate has been shown to cause erosions and
ulcers in rodents and human stomach and to interfere with the
healing of pre-existing lesions (Elliott et al., 1998; Graham and
Malaty, 1999; Wallace et al., 1999). The mechanism through
which alendronate and other bisphosphonates cause mucosal
injury has not been clearly identiﬁed. When bisphosphonates
are administered intravenously, the occurrence of gastritis and
esophagitis is uncommon. Thus, it seems that alendronate pro-
duced damage through topical irritant effects on the gastric
epithelium (Geddes et al., 1994) and the changes in the gastric
microcirculation do not appear to contribute signiﬁcantly to thepathogenesis of epithelial injury (Wallace et al., 1999). Further-
more, it was demonstrated that neutrophil accumulation and
subepithelial edema in the gastric mucosa caused by alendronate
are important for the development of ulcer (Wallace et al., 1999).
The latter effect is associated with increased production of
proinﬂammatory cytokines (IL-1b, TNF-a, and IL-6) (Yamaguchi
et al., 2000; Thieaˆbaud et al., 1997).
In the present study, elevated accumulation of neutrophils and
TNF-a and IL-1b levels along with increased MPO activity in the
gastric mucosa caused by alendronate indicate the contribution of
neutrophil inﬁltration and the impact of proinﬂammatory cyto-
kines (TNF-a and IL-1b) in oxidative gastric damage. Since a
CO-donor and CO precursor inhibited alendronate-induced accu-
mulation of neutrophils in the mucosa, increased MPO activity,
and abolished the TNF-a and IL-1b response concomitantly,
our results suggest that neutrophil accumulation contributes to
alendronate-induced gastric injury. Furthermore, the gastropro-
tective effect of CO may be, in part, dependent on its inhibitory
effect on gastric mucosa neutrophil inﬁltration and neutrophil-
associated TNF-a and IL-1b response.
Our results are in accordance with the literature. Recent
investigations have shown that HO-1/CO inducers increase HO-1
expression in gastrointestinal mucosa and ameliorate mucosal
injury as well as inﬂammatory cell accumulation by decreasing
inﬁltrating neutrophils via inhibition of nuclear factor-kappa beta
(NF-kB)-dependent proinﬂammatory cytokines, suggesting that
CO can mediate the anti-inﬂammatory actions of HO-1. Recently,
Dal-Secco et al. (2010) demonstrated that the HO-1/CO/cGMP
pathway inhibits neutrophil recruitment during the inﬂammatory
response.
Accordingly, it was demonstrated that aminobisphosphonates
induce inﬂammatory reactions in several tissues (Yamaguchi
et al., 2000). In addition to their direct damaging effects on
tissues, it is well established that oxygen metabolites play a role
in the recruitment of neutrophils into injured gastric mucosa
(Zimmerman et al., 1990; Kettle and Winterbourn, 1997).
Activated neutrophils are also a potential source of oxygen
metabolites (Sullivan et al., 2000).
It has been suggested that oxygen-derived free radicals may
contribute to alendronate-induced gastric mucosal lesions and
reduced GSH content in stomach tissues (Sener et al., 2004, 2005).
Therefore, it is possible that the effect of CO may result in a
decreased redox state in alendronate-induced gastropathy. Our
results showed that administration of hemin or DMDC reversed
the decrease in gastric GSH levels after alendronate administra-
tion. Thus, CO may function by decreasing the redox state in
alendronate-induced gastropathy. Therefore, another possibility
is that an increase in GSH levels could be secondary to a decrease
in free radical production. Our results demonstrated that hemin
or DMDC pretreatment resulted in a signiﬁcant decrease in MDA
levels in alendronate-induced gastropathy. In general, it has been
demonstrated that HO-1-derived CO has anti-oxidant properties
against oxidative stress in vivo and in vitro (Mancuso, 2004; Ryter
and Tyrrell, 2000). Thus, the mechanism through which CO exerts
its gastroprotective effect seems to involve the reduction of lipid
peroxidation induced by alendronate in the gastric mucosa.
Recent studies reported that CO has a number of important
physiological properties that are activated through sGC and elevated
intracellular cGMP levels (Gonzales and Walker, 2002; Gomes et al.,
2010). Using a pharmacological approach, we demonstrated that
inhibition of sGC by ODQ reversed the protective effects of a CO
donor (DMDC) and a CO precursor (hemin) against alendronate-
induced gastric damage and ODQ plus alendronate increase the
alendronate effects. Our results are in accordance with the literature.
Some works have demonstrated that CO activates sGC (Ryter and
Otterbein, 2004; Morita et al., 1995) and ODQ treatment completely
N.R.D. Costa et al. / European Journal of Pharmacology 700 (2013) 51–5958abolished the protective effect of HO-1 against non-steroidal anti-
inﬂammatory drugs and ethanol-induced gastric damage (Gomes
et al., 2010; Freitas et al., 2006).
Several studies have suggested that bisphosphonates have a
direct irritant effect on the gastric mucosa (Graham and Malaty,
1999; Blank et al., 1997; Elliott et al., 1998), i.e., to decrease the
hydrophobic barrier (Lichtenberger et al., 2000). This damaging
effect is not due to a decline in the levels of mucosal prostaglan-
dins (Marshall et al., 2000), but through topical irritant action. The
damage in the stomach is accompanied by disruption of the
mucosal barrier, leading to Hþ back-diffusion into the mucosa
(Kanatsu et al., 2004). Furthermore, Lichtenberger et al. (2000)
showed that the topical irritant property of bisphosphonates is, in
part, attributable to the ability of bisphosphonates to chemically
associate with and destabilize the surface lining of phospholipids,
resulting in a rapid decrease in the tissues hydrophobic barrier. In
the present study, we conﬁrmed that alendronate caused a
signiﬁcant reduction in gastric mucus production when compared
with the negative control (saline). Pretreatment with a CO donor
signiﬁcantly increased amount of mucus in the gastric mucosa
wall. However, when the animals were pretreated with ODQ, this
gastroprotective effect was abolished. Studies linking CO with
mucus secretion in the stomach are scarce. However, Brown et al.
(1993) showed that other gaseous mediators, e.g., NO, also
stimulate mucus secretion by rat gastric mucosal cells, and this
effect appears to depend on elevation of intracellular cGMP levels.
In summary, our results indicate that CO prevents alendronate-
induced gastric damage by activation of sGC, decreases direct
oxidative damage, and causes inhibition of neutrophil inﬁltration.
Although there are many mechanisms through which this effect
can occur, our data support the hypothesis that activation of the
HO-1/CO/cGMP pathway is of primary importance. These observa-
tions also raise the possibility that CO-releasing agents could be
used to improve resistance to gastric mucosa injury.Acknowledgments
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